Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. (February 2017) - Kwakman, J.J.M.; Simkens, L.H.J.; Van Rooijen, J.M.; Van de Wouw, A.J.; Loosveld, O.J.L.; Creemers, G.J.M.; Hendriks, M.P.; Los, M.; Van Alphen, R.J.; Polée, M.B.; Muller, E.W.; Van der Velden, A.M.T.; et al.